TNF and COVID-19: Further indirect support comes from observational studies of patients with autoimmune inflammatory diseases, where chronic TNF-α inhibitor therapy significantly reduced the odds of hospitalisation and severe COVID-19 outcomes (defined as ICU admission or death) [42, 43].